REQUEST A DEMO
Total
USD $0.00
Search more companies

Apures Co., Ltd. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Apures Co., Ltd. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in development and distribution of mini pigs used for medical treatment and experiment. The Company sells experimental animals used for nonclinical research under the brand name of MICROPIG. The Company's mini pigs are used for pharmaceuticals, regenerative medicine, xenotransplantation research, development of organ transplant medical equipment and medical technology, as well as other biotechnology fields. In addition, the Company sells bio resources, bio materials and biological agents used for body and tissue engineering. The Company was founded on July 5, 2001 and its shares are listed on KOREA NEW EXCHANGE(KONEX) on September 3, 2019.

Headquarters
44, Hansan-Gil, Cheongbuk-Eup
Pyeongtaek; Gyeonggi;

Contact Details: Purchase the Apures Co., Ltd. report to view the information.

Website: http://www.apures.com

Basic Information
Total Employees:
Purchase the Apures Co., Ltd. report to view the information.
Outstanding Shares:
Purchase the Apures Co., Ltd. report to view the information.
Financial Auditors:
Purchase the Apures Co., Ltd. report to view the information.
Incorporation Date:
December 05, 2025
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Company Performance
Financial values in the chart are available after Apures Co., Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-3.33%
Total operating revenue
-28.82%
Operating profit (EBIT)
40.8%
EBITDA
46.81%
Net Profit (Loss) for the Period
40.37%
Total assets
-10.67%
Total equity
-45.92%
Operating Profit Margin (ROS)
267.56%
Net Profit Margin
301.4%
Return on Equity (ROE)
-7.93%
Debt to Equity Ratio
84.43%
Quick Ratio
-0.16%
Cash Ratio
-0.16%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?